Acesion Pharma raises €45m series B funding

Betsy Goodfellow | September 26, 2023 | News story | Business Services Acesion Pharma, Cardiology, atrial fibrillation, series B financing 

Acesion Pharma has announced that it has closed an oversubscribed €45m series B financing round. This financing was co-led by new US investors Canaan and Alpha Wave, as well as including participation from the Global BioAccess Fund and existing investor Novo Holdings.

This financing is intended to advance development of AP31969, an SK ion channel inhibitor for the oral treatment of atrial fibrillation (AF). It is intended that AP31969 will be developed for chronic oral maintenance treatment to prevent AF recurrence, and will be progressed into phase 1 and 2 trials.

Anders Gaarsdal Holst, MD PhD, chief executive officer of Acesion, commented: “The high levels of investor interest and demand that we saw during this financing speak to the strong data we have generated, both on the novel mechanism of SK channel inhibition in general and the AP31969 compound specifically. This is a powerful endorsement for our team and the quality of our science. With the financing in hand, we are focused on progressing AP31969 into a phase 1 clinical trial later this year.”

Tim Shannon, MD, general partner at Canaan, added: “Acesion is redefining treatment for patients suffering from AF. The impressive preclinical data from AP31969 shows great promise and we are delighted to support Acesion in taking AP31969 through to phase 2 completion.”

Betsy Goodfellow

Related Content


Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns

It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s …

AI accurately detects subtle signs of atrial fibrillation even in normal tests

A new study from the Mayo Clinic shows that artificial intelligence (AI) can detect signs …


Two biomarkers can aid in atrial fibrillation screening, researchers find

A team of researchers at the University of Birmingham has identified a pair of biomarkers …

Latest content